The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Zotiraciclib for newly diagnosed or recurrent glioblastoma: Updated outcome and biomarker analysis.
 
Michael Weller
Honoraria - Bayer; Novocure; Pierre Fabre (I)
Consulting or Advisory Role - Bayer (I); Curevac; Janssen (I); LEO Pharma (I); Medac; Novartis; Orbus Therapeutics; Philogen; Roche; Sandoz; Seagen (I)
Research Funding - Quercegen Pharmaceuticals (Inst); Versameb (Inst)
 
Thierry Gorlia
No Relationships to Disclose
 
Joerg Felsberg
No Relationships to Disclose
 
Joost Jongen
No Relationships to Disclose
 
Claude-Alain Maurage
No Relationships to Disclose
 
Francois Ducray
Honoraria - Novocure; SERVIER
Consulting or Advisory Role - Novocure; SERVIER
Travel, Accommodations, Expenses - Novocure; SERVIER
 
Dorothee Gramatzki
No Relationships to Disclose
 
Peter Hau
Consulting or Advisory Role - BMS Turkey; GlaxoSmithKline; MSD Oncology; Novocure
Speakers' Bureau - Lilly; Novocure; Novocure; Seagen
Travel, Accommodations, Expenses - Medac; Novocure
 
Olivier L. Chinot
Leadership - Betainnov
Honoraria - SERVIER
Travel, Accommodations, Expenses - Carthera; Kyowa Kirin International; Novocure
 
Matthias Preusser
Honoraria - Abbvie; Adastra Pharmaceuticals; AstraZeneca; Bayer; BMJ Journals; Bristol-Myers Squibb; CMC Contrast; Daiichi Sankyo; Gan & Lee; Gerson Lehrman Group; GlaxoSmithKline; Lilly; Medahead; MedMedia; Merck Sharp & Dome; Mundipharma; Novartis; Roche; Sanofi; SERVIER; Tocagen
Consulting or Advisory Role - AbbVie; Adastra Pharmaceuticals; AstraZeneca; Bayer; Bristol-Myers Squibb; CMC Contrast; Daiichi Sankyo/Astra Zeneca; Gan & Lee; Gerson Lehrman Group; GlaxoSmithKline; Lilly; Merck Sharp & Dome; Mundipharma; Novartis; Roche; Sanofi; SERVIER; Tocagen
Research Funding - AbbVie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Merck Sharp & Dohme; Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Mundipharma; Roche; SERVIER
 
Stephanie Cartalat
No Relationships to Disclose
 
Patrick Roth
Honoraria - Merck; Novocure; Roche
Consulting or Advisory Role - Alexion Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; Midatech Pharma; MSD; QED Therapeutics
Research Funding - MSD (Inst); Novocure (Inst)
 
Martin J. Van Den Bent
Consulting or Advisory Role - Anheart Therapeutics; AstraZeneca; Boehringer Ingelheim; carthera; chimerix; Fore Biotherapeutics; Genenta Science; Incyte; Mundipharma; Nerviano Medical Sciences; Roche; Servier
Speakers' Bureau - Servier
 
Julia Furtner
No Relationships to Disclose
 
Maike Collienne
Research Funding - Oncolytics (Inst)
 
Guido Reifenberger
No Relationships to Disclose
 
Tobias Weiss
Honoraria - Philogen
Consulting or Advisory Role - Philogen
Research Funding - Philogen (Inst)
Travel, Accommodations, Expenses - Philogen
 
Emilie Le Rhun
Honoraria - Bayer (I); Novocure (I); Pierre Fabre
Consulting or Advisory Role - Bayer; CureVac (I); Janssen; Leo Pharma; Medac (I); Novartis (I); Orbus Therapeutics (I); Philogen (I); Roche (I); Sandoz (I); Seagen
Research Funding - Bristol-Myers Squibb (Inst)